Authors

Shalini Arunogiri

MBBS (Hons), MSc, MPsychiatry, PhD, FRANZCP, Addiction Psychiatrist, Clinical Lead, Turning Point, Eastern Health, Vic; Senior Lecturer, Monash Addiction Research Centre and Eastern Health Clinical School, Monash University, Vic


The assessment and management of gamma hydroxybutyrate use in general practice

Gamma hydroxybutyrate is associated with a disproportionate burden of harm despite low overall population prevalence of use.


The six Rs of managing high-risk opioid prescribing

Patients prescribed high doses of opioids need to be managed appropriately to reduce risks of morbidity and mortality.